The Latest Cardiac and Vascular News
FLAGSTAFF, Ariz., Nov. 30, 2020 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device. Six-month data for 16 patients enrolled […]
Press release (MAR) Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and further analysis of the FDA approval, Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic type of code and […]
Advanced Healthcare IT AI Solution Can Speed Up Clinical Response and Help Increase Diagnostic Confidence to Take Patient Care to the Next Level TUSTIN, Calif.–(BUSINESS WIRE)–With stroke, the key to improving outcomes is speed. However, busy facilities don’t always have the luxury of knowing when an immediate intervention is needed. […]
Press release (MAR) Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US. “This is a major achievement […]
PHILADELPHIA, Nov. 24, 2020 /PRNewswire/ — The Cardiac Center at Children’s Hospital of Philadelphia (CHOP) is pleased to announce the launch of Pediatric & Congenital Heart Talks, a free, monthly, video-based educational resource for clinical and research professionals in pediatric cardiology. Hosted by Jack Rychik, MD, director of the Fetal Heart Program at CHOP, and featuring discussions with world-class experts […]
Paris, November 17th, 2020 The French MedTech Cardiawave has been granted authorization by the Agence Nationale de Sécurité du Médicament et des produits de santé – ANSM (French National Agency for Health Products Safety) on October 20th to extend its clinical trial in France and treat patients with calcific aortic […]
THOUSAND OAKS, Calif., Nov. 23, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Omecamtiv mecarbil, an investigational selective cardiac myosin activator, was studied in GALACTIC-HF, […]
Significant Reduction in Triglyceride Levels Without Low-Density Lipoprotein Cholesterol (LDL-C) Increase Compared to Placebo and Safety Profile Similar to Placebo Achieved with 4 Grams Per Day Dose of Icosapent Ethyl in Chinese Patients with Very High Triglycerides (>500 mg/dL) Results Support Upcoming Submission by Partner, Edding, Seeking Regulatory Approval in China DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically […]
Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline Indication of rapid and persistent clinically relevant improvement in patients’ quality of life Safety profile in line with expectations Interim data of the full Roll-In Cohort expected in H1 2021 Conference call with live webcast presentation today at 02:00 pm CET / 08:00 am EDT GHENT, Belgium, […]
– In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with type 2 diabetes are […]
